Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II nintedanib versus placebo in previously treated differentiated or medullary thyroid cancer
NL-OMON47685Phase 2Active, not recruiting
- Sponsor
- European Organisation for Research and Treatment of Cancer
- Start
- Jun 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in thyroid cancer, well-differentiated thyroid cancer (WDTC) and Medullary Thyroid Cancer (MTC) comparing Nintedanib with Placebo (2 arms). Primary endpoint: Progression-free survival. Started Jun 2014; status: active, not recruiting.
02
Drugs
nintedanib
03
Conditions
thyroid cancerwell-differentiated thyroid cancer (WDTC)Medullary Thyroid Cancer (MTC)
Beyond the preview
Go deeper on NL-OMON47685.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON47685.